The ParaGard Copper T 380A intrauterine device (CuT380A) provides reversible contraception that is as effective as sterilization for up to 20 years. The CuT380A is a mainstream, first-line contraceptive option for most healthy women, including nulligravidwomen,aswellasmanywomenwhohaveseriousmedicalproblems.Becauseitisthemostcost-effectivemethodofbirth control,theCuT380AisthepreferredIUD,exceptforwomenwhodesirelighterornomenstrualbloodloss.Surveysrevealthat95% ofUSCuT380Ausersare"very"or"somewhat"satisfiedwiththeirmethod.ThisarticledescribescurrentcandidatesforIUDuse,discussesthemechanismsofactionoftheCuT380A,providesguidancetoreducebarrierstoIUDaccess,suggestscounselingpointsfor patients,andoutlinestechniquestoreducetherisksandsideeffectsthatcanbeassociatedwithuseoftheCuT380A.
Introduction
Worldwide, intrauterine devices are the most commonlyusedformofreversiblecontraceptionwith 160millionwomencurrentlyrelyingonthis method. 1 Highest rates of utilization are found in China, Southeast Asia and the Middle East, but as many as 24% of women in select European countries use IUDs. 2 The impact that provider enthusiasm for IUDs has on their utilization can be seen in isolated reports ofunusuallyhighacceptancerates.Onlyabout1.5% ofBraziliancontraceptingwomenuseanyIUDsbut inoneSaoPauloclinic,about40%ofwomenusethe CuT380A. 3 Copper IUDs are the most commonly used type of IUD;over106millionwomenworldwideusethem. 4 The CuT380A (ParaGard ® Copper T380A IUD, Teva Women's Health Inc., Pomona, NY) has been found to be the most effective copper IUD 5, 6 and is the only nonhormonal IUD currently available in the United States. The CuT380A is a T-shaped device, which measures 32 mm vertically and 36 mm horizontally. Its plastic frame is composed of polyethylene with barium sulfate to enhance its radiographic visibility.Athincopperwirewith200mm 2 surface area is wrappedaroundthestemandasleeveofsolidcopperislocatedoneachofthetwoarms,whichraises the total surface area of copper to 380 ± 23 mm 2 . At thebaseoftheverticalstemisa3mmbulbthrough which are threaded the monofilament polyethylene tailstringsthatcanenablethepatienttomonitorfor theongoingpresenceofthedeviceandfacilitatelater removal of the IUD. This IUD is sold in a sterilized package that also includes the introducing tube and thestabilizingrodneededforplacement. TheintroductionoftheCuT380Awasdelayedfor 3 years after its FDA approval in 1985, until 1988 because of the extremely unfavorable medicolegal environment for IUDs at the time. 7 When it was ultimately introduced, product labeling was very stringent,reflectingliabilityconcernsfrombothmanufacturer's and providers' perspectives. In addition to extensive contraindications, which were largely basedontheoreticalconcerns,anewtypeoffilterwas appliedto reducepotential users-a "recommended patient profile" requiring parity, stable mutually monogamousrelationship,andnohistoryofPIDor ectopicpregnancy.
AsexperiencewiththeCuT380Ahasgrowninthe
USandscientificevidencehasbeenmorefrequently usedasabasisforproductlabeling, 8 dramaticchanges have been made in the circumstances in which this IUD is offered. The CuT380A has become a mainstream, first line contraceptive option for women seekingtoptier,intermediatetolongtermcontraception.Itisanexcellentchoiceforwomendesiringto delaypregnancyandalsoisanimportantalternative to irreversible sterilization. When fewer than 30% of women fill their prescriptions for hormonal contraception on time for 12 months 9 and 1 million pill usersbecomepregnanteachyear,thereisaclearneed for an effective contraceptive that requires virtually noefforttomakeitwork.Asaresultofitshighefficacyanditslongdurationofaction,theCuT380Ais the most cost-effective method of birth control. [10] [11] [12] As more insurance companies cover this method, the totalcostofreproductivehealthcarewillbereduced. Foruninsuredwomen,self-payprogramsandpatient assistance programs have considerably extended potential accessibility.
Despite these attractive features, it is estimated thatonly5.5%ofcontraceptingwomenintheUnited StatesuseanytypeofIUD, 13 and only a minority of thosewomenutilizesthecopperIUD.Inpart,thismay reflectlackofprofessionalenthusiasmforthemethod. A recent survey of clinicians reported that 40% did not offer IUDs to anypatientseekingcontraception. 14 A curious pattern of inherent bias appeared in another study of physician responses to standardized patient videos,inwhichitwasfoundthatphysicianstended toofferIUDsonlytolowSESwomenofcolorand highSESwhitewomen. 15 ItisclearthatifCuT380Awereusedmoreoften, unintendedpregnancyrateswouldbelower,aswould reduce repeat pregnancy among adolescent mothers and repeat abortions among women seeking pregnancy termination. [16] [17] [18] [19] For all these reasons, expanding use to younger women has been declared to be a national priority. 20 In order to better appreciate thepotentialthatthismethodofferswomen,thisarticlewillprovideacomprehensivereviewoftheliterature about mechanisms of action, product safety and efficacy,patientsatisfactionandapproachestoreduce therisksandsideeffectsthatcanbeassociatedwith the use of CuT380A.
Mechanisms of Action
Therehasbeensignificantconfusionaboutthemechanisms of action of the Copper IUD, but all the classicscientificevidencedemonstratesthattheIUDisa contraceptive,whichactsafunctionalspermicide,to prevent the sperm from reaching the fallopian tube to fertilize the ovum. [21] [22] [23] [24] The copper ions stimulate an intrauterineinflammatoryreactionthatiscytotoxicto thespermandphagocytizesthem;noviablespermatozoa remain in the endometrial cavity 18 hours after natural insemination. 25 Copper has a direct adverse effect on sperm motility and on sperm ability to penetrate through the cervical mucus. 21, [26] [27] [28] The copper ions also incite inflammatory changes around the oocyte at the time of ovulation, a situation that is similartothatseeninwomenwithendometriosis.
There is no evidence that the IUD works after implantation. Women using IUDs, who were followed with serial measurements of serum β-human chorionicgonadotropin,demonstratednopatternsuggestiveofabortion(initialincreasewithsubsequent disappearance of that hormone). [29] [30] [31] The evidence thatIUDsdonotworkafterfertilizationbyblocking implantation comes from several different experimentaldesigns.Whenlaparoscopictubalflushingswere studied, no sperm were found. 25, 32 By studying ova retrievedduringsterilizationproceduresfromwomen whohadmidcyclecoitus,itwasseenthatnoneofthe specimensfromwomenusingIUDsdisplayednormal cellular division indicating successful fertilization. However,50%oftheovafromthewomenwhoused nomethodshowedsuchdivision. 33 Similarly,noeggs wererecoveredfromtheuterinecavitiesof56IUD userswithin132hoursaftertheLHpeakcomparedto 4eggsfoundinthe115controlwomen. 33 In addition, the fact that CuT380A dramatically decreases ectopicpregnancyriskssupportsthefactthatthesiteof action is before the fallopian tube-that fertilization is blocked. Recent studies have revealed that the copperIUDdecreasesendometrialHOXA10expression, whichisessentialforendometrialreceptivity,butthe clinicalsignificanceofthosechangesisnotknown.
34
When the CuT380A is placed postcoitally, it functions very successfully as an interceptive, but it may be that the placement procedure itself (with its substantial intrauterine manipulation) is responsible for that protection. The inflammatory changes seen in the endometrium, which are responsible for its excellent contraceptive efficacy, take time (at least days) to become established and cannot completely explain the ability of the CuT380A to provide immediateemergencycontraception(seebelow).
Efficacy as Ongoing Contraceptive Method
IUDsareamongthemosteffectiveandsafestmethods of contraception. A 2008 Cochrane Systemic Review concluded that the first year failure rate of the CuT-380A ranged from 0% to 1.0%; the cumulativepregnancyrateby10yearswas2.1%innon-Chinese study centers, but 4% in Chinese centers, whichtendedtohavelessloss-to-follow-up. 5 Similar estimates were obtained by a later review in which theCuT380Awasfoundtohavea5yearfailurerate of0.3%-0.5%. 35 These rates compare very favorably tothepregnancyratesseenwithtuballigation.
36
Longer follow-up studies have demonstrated that the CuT-380A provides highly effective contraception beyond 10 years. Excellent protection was reported in one study for up to 15 years. allergies.
43
IUDs containing smaller amounts of copper have measurably higher failure rates than the CuT380A. 26 Forexample,theNovaTwithonly 200 mm 2 of copper has a first year failure rate of 1.42%. 5 Some investigators have suggested that the intrauterine concentrations of copper ions, especially the early burst effect, might induce cytoxic and genotoxic effects on endometrial cells. 44 Higher concentrationsberesponsibleforearlyspottingand bleeding,buthavenolongtermcarcinogenicimpacts on the endometrium. 44 
Copper IUDs for Emergency Contraception
Inareviewof8400postcoitalcopperIUDplacements, Trussell and Ellerson reported that pregnancy rates ranged between 0.1% and 0.7%. 45 A 2-year study compared 98 women who had IUDs placed postcoitallyforbothemergencyandfuturecontraception withacontrolgroupofwomenwhohadroutineIUD placementforpregnancyprotectiononly;itfoundno differenceinratesofpregnancy,expulsionorremoval formedicalreasonsbetweenthe2groups.
46
In the first prospective study of the effectiveness of the CuT380A as an emergency contraceptive,noneof1963womenwhohadthatIUDplaced within120hoursofunprotectedintercourseexperi-encedpregnancyinthefirstyear.The12monthcon-tinuationrateamongthe1493womenwhoremained inthestudywas94.3%formultiparouswomenand 88.2%fornulliparousones. 47 In another multicenter study involving 1933 Chinese women who had the CuT380A placed within 120 hours of unprotected intercourse, the observed first year pregnancy rate was 0.13%. 48 Confirming these high levels of efficacyisatrialofanotherIUDwithslightlylesscopper (375mm 2 )asanemergencycontraceptive,inwhich thepregnancyratewas0.2per100women-years. 49 These rates compare very favorably to the single episode failure rate (2.0%) of the levonorgestrel emergencycontraceptivepill.Asseen,womenoften utilize the CuT380A for ongoing contraception. In aprospectivecomparativetrialofwomenchoosing CuT380A vs. oral levonorgestrel tablets for emergencycontraception,itwasfoundthatat6months, 61% of women continued to use their IUDs and another8%hadswitchedtoanothereffectivemethod whereasonly52%oftheoralECuserswasusingan effective method.
50

Other Health Benefits Provided by CuT380A
BecausetheCuT380Aprovidessucheffectiveprotec-tion against pregnancy, it also significantly reduces awoman'sriskofdevelopinganectopicpregnancy. Women who use no method of contraception are 2-10 times more likely to experience an ectopic pregnancy than are CuT380A users. 51, 52 If a woman does become pregnant while using the CuT380A, herriskofhavinganextrauterineimplantation(8%) islower thanwomen who getpregnant whileusing the LNG-IUS or following tubal sterilization. 53 The CuT380Ahasalsobeenassociatedwitha50%to60% reduction in the risk of endometrial adenocarcinoma, althoughthemechanismofactionforthisprotection is not clear.
54-58
Patient Satisfaction
The success of the CuT380A can be measured not onlyintermsofefficacy,butalsointermsofacceptanceandcontinuationrates.WorldwidethepopularityofthecopperIUDsreflectshighacceptancewhere the devices are available. 59 IntheUnitedStates,atremendous potential for IUD utilization has been demonstratedbystudiesinwhichlongactingmethodsare provided for free. 60 Patient satisfaction with the IUD is generally amongthehighestofallmethods. 61 Continuation rates withtheCuT380Areflectthatsatisfaction;firstyear continuation rates are relatively high, 85%-90%, 39 comparedtocontinuationrateswithotherreversible methods.A WHO study found that 44% of women continued to use their CuT380A for at least 7 years. 62 NotonlydowomenuseIUDsforlongerthantheyuse other methods, they use them more effectively. There is no intermittent or inconsistent use of the CuT380A, asisroutinelyseenwithothermethods.
63,64
One of the most common reasons for early IUD removalisadesireforpregnancy;onaveragewomen usethecopperIUD4yearsbeforerequestingremoval for this reason. 65 Cost effectiveness is established in less than 2 years. 12 A removal request provides an opportunityforpreconceptioncare,whichisnotroutinelyavailablewithmostothermethods.Womenwho experiencesideeffectstendtorequestslightlyearlier removal, which might be affected by the patients' concerns about the impact of the side effects. 66 
Candidates for IUD Use
The United States Medical Eligibility Criteria published by the CDC in May 2010 lists only a limited number of medical conditions as Category 4 (contraindications) for use of the CuT380A. 67 These conditions can be grouped into 4 major categories-1) uterine issues (unexplained uterine bleeding;2)endometrialcavitiesthataredistortedor too small (,6cm)ortoolarge(.9cm)),knownorsuspected carcinoma of the uterus (endometrial, cervical); 3) recent uterine infection (cervicitis, endometritis, pelvic inflammatory disease); 4) behavioral conditions(thosewhichplacethewomenathighriskfor PID).Otherthanthoseconsiderations,theCuT380A is a viable option to provide top tier contraception to women with serious medical problems 68 including hypertension, diabetes, 69 ovarian carcinoma, 70 thyroid dysfunction, organ transplant, 71 obesity, breast cancer, history of stroke or myocardial infarction. Someoftheseconditionsarediscussedinmoredetail below. It is interesting to observe that even after a simplified checklist reflecting WHO MEC for IUD usewasprovided,clinicianscontinuedtorelyontheir prior "knowledge"ofIUDeligibilityanddeniedthe IUDto30%ofMEC-eligiblewomen. 72 Perhaps, this may explain why, women are so ill-informed about the IUD. 73 
Nulliparous women
Nulliparity has never been a contraindication to the use of any IUD. However, in the wake of the Dalkon Shield lawsuits (which linked IUD use and PID-relatedinfertility), 74, 75 paritywasarequirement in the recommended patient profile for each of the USIUDs.ThisignoredtherichhistoryintheUSof IUDusebyyoung,nulliparouswomen.Infact,inthe 1970s, the Copper-7
In 2005, the FDA removed the recommended patientprofileinitsentiretyfromtheproductlabeling for the CuT380A. The data that persuaded the FDA to makethissubstantialchangecamefromstudiesthat demonstrated 3 important conclusions: 1) that prior IUD use was not a risk factor for infertility, 2) that the presence of an IUD did not increase a user's risk ofhavingacervicalinfectionascendintotheupper genitaltract,and3)thatdiscontinuationratesamong nulliparouswomenwereacceptable.
Hubacher et al provided the greatest reassurance thatpriorIUDusewasnotassociatedwithinfertility. In a case-control study of 1895 nulliparous woman withprimaryinfertility,noincreaseintheprioruse ofIUDswasfoundin358womeninthetubalocclu-sion group when they were compared either to the 958 infertile controls or to 584 pregnant controls. Tubal infection was not related to the duration of IUD use but was associated with the presence of chlamydia antibodies. 76 Doll et al found that delivery ratesfortheformerIUDuserswereverycomparable to delivery rates seen in women who stopped oral contraceptive use. 77 Itisnotcleariflongerduration ofIUDuseisassociatedwithlowerfertilityrates.
77,78
Hov et al found no difference in overall return to fertilitybetweenwomenwhohadtheirIUDsremoved in order to conceive and those who had their IUDs removed because of an IUD complication. 79 Not only is future fertility not effected by IUD use, but return to fertility is very rapid after IUD removal.
79,80
The concern for an increased risk of PID among nulliparous women was one of the reasons the IUD was lost from the US market in the mid-1980s, 74, 75 but conditions have radically changed since then. The possibility that an IUD might permit the ascent ofthepathogensfromthevaginathroughthecervical mucusintotheuppergenitaltrackwascrediblewith the multifilamenttailstringsoftheDalkonShield.
74,81
However, the monofilament tailstrings used with modern IUDs do not pose that risk. When adjusted for relationship stability, modern IUD users have been foundtohavenoincreasedriskofPIDoverthegeneral population.
74,82
The only time women are vulnerable toanyIUD-relatedincreaseinuppertractinfectionis withinthefirst20daysfollowingIUDplacement.
83,84
Another convincinganswerto theconcern that IUD usemightimpactuppertractinfectioncomesfromthe fact that the treatment of PID in IUD users is the same as it is for other women; the CDC STD Treatment GuidelinesnolongercallforroutineIUDremovalas part of the initial treatment of PID in IUD users. The final concern-that there would be higher rates of side effects and discontinuation by nulliparous women-was addressed in another series of studies. The expulsion rate among nulliparous IUD userswasfoundtobeonlyslightlyhigherthanparous IUD users. 86, 87 Veldhuis et al reported that nulliparous women using "copper IUDs" did not show higher rates for complications than parous users did: PID rateswere3.5per1000women-years;ectopicpregnancy rates were 0.6% to 1.1% per year; and rates ofexpulsionwere0.0%to1.2%peryear.Therewas also no excessive removal of IUDs among nulliparouswomencomparedtoparousones. 88 Even thoughACOG recommends that IUDs and implants be first-line choices for both nulliparous and parous adolescents, 89 teens are rarely even told aboutIUDs.Recentstudieshaveshownthatonlyhalf of the pregnant women aged 14-25 had ever heard about an IUD and only slightly more than one half knewofitsefficacy. 90, 91 AlthoughphysiciansrecommendIUDstoonly42%-86%ofwomenofallages, 15 youngwomencomprisetheagegrouptowhompractitioners are least likely to offer IUDs.
14 In a survey of California women age 14-27 (85% nulliparous), only45%hadheardoftheIUDandnotonewoman hadusedone.Veryinterestingly,afterreadingabrief description of the IUD, only 11% said they might beinterestedinusingone. 92 However,anotherstudy showedthatabrief(3minute)educationalinterventionsignificantlyimpactedontheattitudesthatyoung womenhadtowardsIUDs.Atbaseline,only14.7% of women aged 14-24 expressed a positive attitude towardtheIUD,but,aftertheeducationalintervention,53.8%heldapositiveattitude. 93 
Breastfeeding women
Breastfeedingwomenareexcellentcandidatesforthe CuT380A once uterine involution is achieved. While lactational amenorrhea is a very effective method for the first 6 months following delivery, many women discontinuebreastfeedingearlyandwithoutconsulting their providers. 94 Having the IUD in place providesprotectionduringthosegapsandsimplifiesthe woman'slifeatatimewhenextensivedemandsare beingplacedonhertime.
Breastfeeding women are more likely than nonbreastfeeding women to have a smooth, pain-free IUD placement and less post-placement bleeding and problems. 95 Aprospectivestudyofbreastfeeding womenusingCuT380AIUDcomparedtothoseusing a progesterone-releasing vaginal ring demonstrated thesafetyofIUDuseinthispopulation.Amongthe 97 women using the IUD, there were no insertion failures, no perforations, no pelvic infections, and no accidentalpregnanciesduringthe12-monthfollow-up period. The total discontinuation rate over that year for theIUD was 2.3%, whichcomparedveryfavorablytothe65.4%discontinuationrateseenwiththe progestin-onlyvaginalringinthesametimeperiod. 96 In another prospective randomized trial of IUD usebybreastfeedingwomen,itwasshownthatmean infant weights were at or above the 50 percentile. No negative influence on infant development was observedamongIUDusers.By12months,90.9%of womenwerestillusingthecopperIUD. 97 
Women with uterine leiomyoma
Leiomyoma pose several potential problems for successful IUD use. Fibroids that distort the endometrial cavity can block entry into the endometrial cavity, preventingcorrectplacementoftheIUDatthefundusor they can prevent the IUD arms from extending completely.Anotherconcernisthatbyerodingagainstthe leiomyoma,theIUDcouldcauseunscheduledbleeding orheavyandprolongedmenses.Thedepthofthecavity andthelocationofthefibroidscanbeevaluatedultrasonographically prior to attempting IUD placement. Salineinfusionsonographycanseparatetheendometrialwallsandbetteridentifyanysubmucosalfibroids.If imagingstudiesarenotavailable,theendometrialcavitycanbeadequatelyassessedusingtheuterinesound at the time of attempted IUD placement. If the sound can be advanced easily to the fundus, the uterine depth canbeconfirmedandobstructingfibroidscanberuled out.Lateral(sidetoside)movementofthesoundatthe fundusconfirmsthatthereisadequatespacefortheIUD armstoopencompletely.Womenwhohavesmallleiomyomaandheavymenstrualbleedingareoftenbetter servedbytheLNGIUS 98 or other hormonal methods but,intheabsenceofexcessivemenstrualbleedingand cramping,womenwithsmallfibroidsmaystillreasonable candidates for the CuT380A.
Women with HIv
Women with HIV infection may also use IUDs. In a prospective 2-year trial of HIV-infected women randomized post partum to receive a CuT380A or hormonalcontraceptive(eitherDMPAororalcontraceptives),thesafetyandefficacyofIUDusethispopulationwasestablished. 99 
100,101
Risks of IUD Placement Uterine perforation
Rare complications can occur with IUD placement. Perforationoccursinabout1in1000cases(0.21/1000 to3.6/1000placements).
62,102-104 All perforation starts atthetimeofIUDplacement,butthediagnosisofIUD perforation is often delayed. 105, 106 There is no evidence thattheIUDcanmigratecompletelythroughthemyometriaofnon-pregnantwomen,althoughtheIUDis known to wander within the endometrial cavity. 
Close adherence to all steps of the placement is important to minimize the risk of perforation. This includes placement of the tenaculum to stabilize the uterusandtostraightenitsaxis.Soundingoftheuterus prior to placement will reveal the uterine angle as wellassizeofthecavitytoverifythatthedepthof the uterus (external os to fundus) is within labeling recommendations (6-9 cm). Additional recommendations to limit the risk of perforation are discussed belowinTable 1.
Uterine perforation is suggested when the tailstrings of the IUD shorten or disappear from the vaginaentirely.Probetheendocervicalcanalforthe Table 1 . Management of IUD complications.
Challenges Suggestions
Obesity making bimanual exam inconclusive
Rectal exam can provide assessment of uterine size, mobility, position, etc.
Stenotic cervical os
Progressively dilate cervix with cervical os finder. If unable to dilate cervix, consider misoprostol. 163 vasovagal reaction anticipated Provide a paracervical block-wait at least 3 to 5 minutes. Always be prepared with smelling salts, oxygen, etc. If patient experiences a strong vasovagal reaction, remove cause (IUD, tenaculum, etc.).
Perforation risk
Place tenaculum on cervical lip that is more difficult to reach to more completely straighten the axis of uterus. Pain with tenaculum placement Use of slender tipped tenaculum (Goldstein Grippers) decreases pain and results in less bleeding after removal. Do not have the patient cough with tenaculum placement but having her valsava prior to and throughout may help distract her and stabilize her cervix for tenaculum placement. Perforation potential with uterine sound Gently bend (metal) tenaculum to match uterine flexion. Hold tenaculum as if it were a pencil. Stabilize your hand against patient's thigh. Advance though os using only force of fingers. Advance into cavity in direction of uterus determined during pelvic exam. Loading of IUD into tubing Tuck IUD arms into tubing through packaging. No sterile gloves needed. Prevent future tailstring complaints Cut tail strings long enough to tuck around cervix (eg, behind cervix of anteverted uterus or anterior to cervix of posterior uterus). Pain immediately following procedure Prophylactic NSAIDs do not reduce pain scores 166 but administration with onset of symptoms may be helpful.
IUDortwistacytobrushinthecanaltodetermineif thetailstringsarepresentthereandcanbesnagged andbroughtbackintothevagina.IftheIUD isnot found in the cervix, its localization is usually made ultrasonographically.Ifultrasonographyisnotavailable,theCuT380AcanclearlybeseenonX-raystudies. However, X-rays will not be able to ascertain thelocationofthedevicewithinthepelvis.Markers, suchasauterinesound,helpdefinetheendometrial cavity on cross tableandlateralX-rayfilms.IfX-ray studies are not available, the CuT380A can often be located within the endometrial cavity and removed with alligator forceps, RetrieveHC ® or the Emmett Thread Retriever ® . 108 IUDhooks,whichwerehelpful in removal of S-shaped Lippes Loop IUDs, should not be used to remove T-shaped devices because theyareassociatedwithanincreasedriskofuterine perforation.
If the CuT380A is extrauterine, it should be surgicallyremoved,especiallyifthepatientissymptomatic. This is because the copper may establish a sterile abscess in the peritoneal cavity, which can lead to adhesion formation. These adhesions may cause chronic pelvic pain and infertility. IUDs have alsobeenfoundtocausebowelperforation. 109 There are case reports of delayed abdominal abscesses, up to35yearsafterplacement.
110
Laparoscopicremoval is generally successful.
111
However, with unusual placement (such as within the bladder, 112 rectum, or broad ligament), other surgical approaches may be required. If the patient is asymptomatic and is a poorsurgicalrisk,ithasbeensuggestedthatshemay be intermittently monitored radiographically and symptomatically. 113 expulsion Symptoms of expulsion include vaginal discharge, cramping or pelvic pain, unscheduled spotting or bleeding,dyspareunia(patientorpartner),lengtheningtailstrings,oranIUDpalpatedinthevagina.
114
A Cochrane systematic review reported that first year expulsion rates ranged from 2.4%-5.2% for the CuT380A.
5 Amultinationaltrialwith7yearsof follow-upfoundthatthecumulativediscontinuation rateduetoexpulsionwas1.8per100women-years of use.
115
Expulsionratesareaffectedbytheexperience of the clinician, the parity of the patient, severe dysmenorrhea, and the cycle day of placement. 116, 117 Nulliparous women have a statistically (but not clinically) significantly higher rates of expulsion compared to multiparous women. 86 Expulsion rates are highest when IUDs are placed when women are on menses; delaying IUD placement until cycle day6canreduceexpulsionsinthefirst3monthsby 30%-50%.
118
Breastfeeding women who experience more uterine contractions were found to have no higher expulsion rates than women who menstruated. 96 Awomanwhohasexperiencedonepriorexpulsion has a 30% chance of expelling a subsequent copper IUD.
119
In a large multicenter clinical trial, Walsh et al observedthatearly(duringthefirst8weeks)expulsionswereobvioustothepatient.However,between 8 to 12 weeks, asymptomatic partial expulsions tended to replace those overt, complete expulsions. Thisobservationhasprovidedtheimpetusforthenew recommendationswhichchangethetimingofthefirst follow-upvisitto10-12weeksfollowingplacement.
Infection
As noted above, the risk of pelvic inflammatory disease (endometritis/salpingitis) is elevated among IUD-users only for the first 20 days following IUD placement. 83, 84 Afterthattime,theriskfor acquiring PIDmirrorstheratefoundinthegeneralpopulation. TheseobservationsconfirmtheconceptthatearlyPID results from endometrial contamination at the time of placement and that subsequent infections (with the exception of actinomycotic infection) are due to the same risk factors that non-IUD users have for PID, eg,multiplesexpartnerscombinedwithlackofcondom use.
TheabsoluterateofPIDwithearlyIUDusevaries withtheprevalenceofcervicalinfectionsinthepopulation.InstudiesfromtheUSandNorway,theincidenceearlyinfectionwasapproximately1:1000.
120,121
Inasystematicreview,Mohllajeeetalreportedthat the absolute risks of PID were 0.27% for women withoutSTDsatthetimeofIUDplacementand0.5% amongwomenwithchlamydiaorgonorrhea.
122 These were confirmed by Faundes et al. 123 These observationsunderscoretheneedtoscreenwomencarefully for risk factors which might place them at risk for havingcurrentcervicitis.Theyalsohighlighttheneed forfastidiousattentiontocorrecttechniqueswithIUD placement to minimize endometrial contamination.
However,routineantibioticprophylaxisatthetimeof IUD placement is not warranted. 8, 120 Cervical infectionsanduppergenitaltractinfectionsacquiredduring IUD use can generally be treated with the IUD in placeaccordingtoCDCSTDTreatmentGuidelines, 85 unless the patient fails to respond to antibiotic therapy or actinomycotic PID is suspected. 83, 124 Pelvic actinomyces is an extremely rare disease that can occur in women who use IUD for a long duration. Because it is so rare and because it is not a reportable disease, there are no secure estimates of its incidence. Actinomycesareobligateanaerobic Gram-positivebacillithatarecommensalorganisms found in the mouth and gastrointestinal tract. They arefastidiousandslowgrowing,whichmakestesting forthemchallenging.Theytendtoformgranulomatous abscesses with tissue fibrosis and sinus formation.Theoriginalabscessmaybeunilateral,butthe colonies spread aggressively, often into the bowel. Unlessapatientpresentswithasurgicalemergency (obstruction,etc.),longterm(atleast30days)antibiotictherapywithpenicillin,clindamycin,erythromycin or tetracyclines can be quite effective. 125 In contrasttoPIDcausedbySTDs,itmaybeprudentto removetheIUDafterinitiatingantibioticsinwomen withsuspectedactinomycoticinfection.
126,127
Unfortunately,therearenoscreeningteststoidentify at-riskwomenandfewteststoconfirmthediagnosis ofactinomycoticinfection.Vaginalcultureisnothelpful. 128 Papsmearsareveryinsensitiveandnonspecific fordetectingthepresenceofActinomyces; only about 50%ofwomenwithActinomyces abscesses have pap smearsreportingthecharacteristic"sulfurgranules". The test also results in frequent false positive results, becausemanyotherorganisms(Candida, Aspergillus, Nocardia, Leptothrix, botryomycosis, coccobacilli andevensyntheticfibers)cancausesimilarappearing "sulfurgranules"onpapsmears. 129 The prevalence of Actinomyces-positivesmearsinstudiesofIUDusers were found to vary from 0% to 31%, with an average of 7%. 130, 131 Given its prevalence, an incidental findingofactinomyces-likeorganismsinapapsmear obtained from an asymptomatic woman requires no treatment.
129
IUDs are not generally recognized as a risk factorforvaginalinfectionbut,therearesomeisolated reports of an increase in the incidence of bacterial vaginosisinIUDusers. 132 In addition, Chassot et al havereportedtheIUDmightserveasareservoirfor Candida albicans.
133
Side Effects
On average, menstrual blood loss may increase by 35%-80% with use of the CuT380, but this rarely leads to anemia. 134 Inthefirstyearofuse,heavymenses and dysmenorrhea are the most common reasons for CuT380A removal;
135 up to 15% of users discontinue use due to those side effects. 5 Many more women complain of these problems but tolerate them.Along-termstudyofcopperIUDusersfound thatmeanhemoglobinlevelswerenotchangedfrom baselinebutwomenoverage30werelesslikelyto complain of heavy bleeding. 39 Nonsteroidal antiinflammatory agents (NSAIDs) are frequently recommended to treat each of those side effects. In a systematicreviewof15randomized,controlledstudies involving more than 2700 women, Allen et al foundthatalltypesofNSAIDs(includingalclofenac, diclofenac, flufenamic acid, ibuprofen, indomethacin, mefenamic acid, naproxen and suprofen) reduced bleeding. However, prophylactic use of NSAIDs to prevent development of those side effects is not supported by evidence. 136 IfNSAIDsarenotsuccessful asfirstlinetherapyforheavyorprolongedbleeding, then tranexamic acid may be helpful. For women whohaveaCuT380Aplacedatthetimeofabortion, thenumberofdaysofbleedingandspottingrapidly stabilizes at about 8 days per month. 137 Theprevalenceofbleedingandpainfulsideeffects over time was studied in a 52 week clinical trial of 1947 copper IUD users, in which only 15 subjects werelosttofollow-up.Inthefirst9weekperiod,35% of participants reported more menstrual pain with the IUD. 138 Overtheremainderofthe1yearperiod, about one third of women reported more menstrual painwiththeIUD,butaboutaquarterreportedless menstrualpain.Bleedingwasfoundtodecreaseover time, but intermittent spotting and bleeding complaintsremainedunchangedwithlongertermuse.
One recent report suggests that in women who complained of excessive bleeding or cramping, athree-dimensional(3D)pelvicultrasoundstudy,can behelpfulinidentifyingmalpositionedIUDs(thatmay becausingthoseproblems). 139 Doppler studies have searched for underlying vascular changes, which could account for these complaints but no consistent Clinical Medicine Insights: Women's Health 2011:4 findings have emerged. Jimenez et al demonstrated that women, who have severe dysmenorrhea and/or bleeding with the CuT380A, have increased subendothelial blood flow, but no increase in pulsatility index or in resistance index in the midluteal phase 3 months after placement. 140 The increased blood flow persisted even after corrections were made for age,IUDtypeandparity.YigitetalstudiedIUDusers in the early phase of the menstrual cycle and found thatwomenwithincreasedbleedingscoreshadsignificantlyloweruterinearterypulsatilityindicescomparedtoIUDuserswithoutbleedingproblems.
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Because changes in bleeding patterns are among the most common reasons for IUD discontinuation, Stanback and Grimes sought to determine if such removalscouldbepredictedataone-monthfollow-up visit.Theyfoundthatwomenwhocomplainedattheir first visit of intermenstrual bleeding were 2.9 times more likely to request early removal and those with excessivemenstrualflowwere3.5timesmorelikely todiscontinueuse.Theseauthorssuggestedthatthese womenwouldbenefitfrommoreintensivecounselling and treatment with non-steroidal anti-inflammatory drugstoreducetheriskofearlydiscontinuation.
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Placement Techniques
TheproceduretoplacetheCuT380Aisverystraight-forward. Failures occur in 1 in 300 attempts. 5 The manufacturer's instructions are clearly described in thepackagelabeling 143 and didactic aids are available fromvariousorganizations,includingtheAssociation of Reproductive Health Professionals. 144 
Timing
The CuT380A IUD can be placed at any time in a woman'scyclewhensheisnotpregnant.ItispreferabletoavoidIUDplacementduringmenstruation, especiallyduringheavyflowdaystoreducetherisk of expulsion during the first 3 months.
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Since the Copper IUD is an excellent post coital contraceptive (see above), recent unprotected intercourse is not a contraindicationtoIUDplacement.TheACOGCommitteeonGynecologicPracticeurgedcliniciansadopt SameDayIUDplacementprotocols. 145 
Post abortal placement
The safety and efficacy of IUD placement immediatelyfollowingfirstorsecondtrimesterabortions,is wellestablished. 146, 147 Placement at this time has many attractivefeatures.Thepatient'smotivationisgenerallyquitehigh,especiallyfollowinganelectivepregnancy termination. From the patient's perspective, the convenience of having an IUD placed immediately canbeimportant.Thecervixisopen,makingtheprocedurelessuncomfortableandthebleedingrelatedto IUD placement may be masked by postabortal bleeding. The alternative-delayed placement-may not be feasible because studies have shown that up to two-thirds of women, who asked for an IUD at the timeoftheabortionbutweretoldtoreturnatalater date, never got an IUD placed. 148, 149 Not unexpectedly,IUDusewashigheroverallamongthosegiven the IUD immediately after the procedure.
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ThedisadvantagesofIUDplacementimmediately followinganabortionhavealsobeenchronicled.The greatesttheoreticalrisksareforperforation,expulsion andinfection.Studies,whichhavecomparedimmediate to delayed placement of the CuT380A, have reported that continuation rates by 6 months were equivalent.By12months,expulsionrateswerehigher in the postabortal arm but ranged from 1%-15%. 150 Expulsionratesaregenerallyhigherfollowingplacement done after 2nd trimester abortions than after 1st trimester procedures.
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Postpartum placement of IUDs
Immediate postpartum placement of IUDs is a commonpracticeinMexico,China,andEgypt.Theconvenience to the woman of having an IUD placed immediately(within10minutes)afterdeliveryofthe placentaisobvious;howeverthepotentialforsignificantlyhigherriskofexpulsionmayoffsetthatconvenience. Early followup may be appropriate. 152 In an earlyretrospectivestudy,whichfollowed235women inwhomtheCuT380AIUDwasplacedimmediately following removal of the placenta, the unplanned pregnancyratewas0.7%andcontinuationratesat6 and12monthswere87.6%and76.3%. 153 In another study, which compared immediate postpartum IUD placement to delayed postpartum placement, one yearpregnancyrateswerehigherintheearlyplacementgroup-4.7%vs.2.4%. 154 Inatrialcomparing 910womengivenimmediatepostpartumplacement eitherdigitallyorwithinstruments,6monthfollowup revealed no pregnancies, no infections, no perforations, and expulsion rates of 13.3% vs. 12.7%. AddingappendagestotheIUDhasbeenfoundnotto be helpful.
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Post cesarean-section placement
Case series of IUD placement at the time of cesareansectionhavedemonstratedhighlevelsofdevice retention [156] [157] [158] [159] andlowlevelsofcomplications. 155, 158, 160 Many of the early reports were with tailless IUDs. A recent pilot study of women undergoing elective C-sectionshadTCu380Asplacedthroughtheuterine incisionsandtheelongatedtailstringswerethreaded within the placement tubing through the cervix and intothevagina;allIUDsstayedinafundalposition throughout uterine involution and tailstrings were alwaysavailableinthevaginatofacilitateeasyIUD removal should complications develop. 161 
Preparing for placement
Once a history has been obtained to determine if the patient has any contraindications to use of the CuT380A, a pelvic exam should be done to assess uterinesize,positionandmobility.Nospecificlaboratorytestsareneeded;inparticular,routinescreening for STDs is not needed. Similarly, routine pretreatment with antibiotic prophylaxis or with 162 or with misoprostol is not recommended. 163 Suggestions to increase successful IUD placement are outlined on Table 1 .
Infection issues with IUD placement
Known acute cervicitis is an absolute contraindication to IUD placement until the infection has been cleared.However,routinescreeningforSTDsorcervicalcytologyisnotrequired. 140 Iftestingisdone,it may be obtained on the day of the procedure. One studyof975IUDplacementsfoundthatnoneofthe women,whowerediagnosedwithchlamydiaimmediately following placement, developed PID when alltheinfectedwomenweretreatedwithin7daysof IUD placement. 121 TheriskofdevelopingclinicalPID attributabletoanIUDhasbeenestimatedtobe0.15% whentheprevalenceofgonorrheaandchlamydiain the population was 1% and there was screening for STDs.
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There is also no longer any concern about CuT380A placement in the face of vaginal infections, such as bacterial vaginosis or candidal infection.Women who have trichomoniasis should be re-evaluatedascandidatessincetheyhavedemonstrated their vulnerability to STDs in a sexual relationship. If a woman has bacterial vaginosis, IUD placement should not be delayed, but she shouldbegivenoralantibiotictherapy,notvaginal treatments, for her condition.
Managing discomfort during IUD placement
Everyeffortshouldbemadetoreducediscomfortand the fear of discomfort with IUD placement. There are several potential steps in the procedure which might cause pain or discomfort. Most women rate theirdiscomfortasmildtomoderate.Occasionally, the pain is more severe and may be accompanied by nausea, dizziness and vasovagal reactions. Cramping and pain may last for a few days. Risk factors forpainincludenulligravidity,ageover30andmore timesincemenses.Expectationsalsoaffecttheperception of pain. 66 Earlystudiesofpainwithplacement of the Dalkon shield found that pain scores were unaffected by pretreatment with NSAIDs. 165 OthertrialswithNSAIDsofdifferentdosesanddifferentformulationshavealsofailedtofindabenefit. In one study, median pain scores on a scale of 1 to 10were1.8intheibuprofengroupand2.0inpla-cebo users. 166 Misoprostol given sublingually with diclofenac does not reduce pain and may increase side effects. 167 Double-blind, randomized, placebo controlled studies of the effect of misoprostol failed to show any positive impact on pain scores or the ease of placement of the IUDs. 163, 168 However,ina smallpilotproject,useofmisoprostol400mcggiven vaginally 1 day prior to IUD placement enabled women,whohadpreviouslyfailedplacementdueto cervical stenosis, to receive an IUD. 169 
Management of pregnancy with IUD use
Oncepregnancyhasbeendiagnosed,itis important to localize both the IUD and the pregnancy. If the copper IUD fails, the chance that the pregnancy is extra-uterine rises to about 5%-8%, 170 which is far less than is seen with either tubal ligation or the progestin-releasingIUDS.Ontheotherhand,ofthe most frequent reason for pregnancy in an IUD user is that the IUD has been lost or dislocated. 171 If the pregnancy is intrauterine and diagnosed in the first trimester, the CuT380A should be removed if removal canbeaccomplishedwithoutaninvasive procedure.
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Early removal reduces the risk of spontaneous abortion, septic abortion, and pre-term delivery.
21
Womenwithnoavailabletailstringsshouldbecounselledaboutthesignsandsymptomsofpretermlabor, but advised that they face no increased risk of fetal anomaliesduetothepresenceoftheCuT380Awithin the endometrial cavity.
Other Issues
Womenwhorequirebiopsiesofendocervicalareaand endometriumcangenerallyhavethemdonewithout disruptionoftheIUD.LEEPprocedurescanbedone either by lifting the tailstrings away from the area, tuckingthemtemporarilyinsidethecervixorprotectingthemwithinaplastictubing.
173
Womenwhoneedimagingcansafelyundergomagneticresonanceimagingwithoutconcernsforheating theCuT380Aorrotationalforcesbeingappliedtothe unit. 174 Counterfeit IUDs are now available on line and have tempted providers who wish to make the devices available to their patients. Unfortunately, these devices are not allowed by the FDA and use of them has been found to constitute insurance fraud. Themanufacturerhasprogramsinplace(patientpaymentplansandpatientassistanceprograms)toreduce theinitialupfrontcostsothatwomencanenjoythe longtermcosteffectiveness,andotherbenefitsofthe CuT380A.
Looking into the Future
ThebenefitsoftheCuT380Aarewelldocumented. (SeeTable2),andshouldbecomebetterrecognized with time. Utilization of IUDs in the US will continuetogrow,especiallyassmallerdevicesareintroducedforuseinnulliparouswomen,asmorewomen learn of the convenience and efficacy of IUDs and as more clinicians have success placing them. The CuT380A, in particular, may well gain more favor when cost effectiveness becomes a more important focus for the health care system. It is not clear if the more innovative applications (including immediate postabortal or postpartum placements and use of the copper IUD as an effective emergency contraceptive)willbemoregenerallyadopted,sinceeachof themwouldrequirechangesinthewaypaymentsare made.Inparticular,ifglobalfeescontinuetobeprovided for obstetrical care, it is unlikely that immediate postpartum placements will increase. Copper IUDsthatarecoatedwithNSAIDsorrelatedcompoundsmayreduceearlyspottingandunscheduled bleeding.VersionsofthecopperIUDthatrestinthe cervixratherthanwithintheendometrialcavitycould greatlyincreasethenumberofclinicianscapableof offeringthisdevice. Table 2 . Key points: CuT380A in 2011.
• The Copper T380A is the most cost effective method of birth control available in the United States.
• The efficacy of the CuT380A in typical use matches that of sterilization and places it in the top tier of methods.
Therefore, the CuT380A is a mainstream, first choice method for all women, except those who do not want monthly bleeding.
• Off label, the CuT380A may be used for up to 20 years.
• Return to fertility is rapid following removal of the CuT380A.
• Patient satisfaction is among the highest and continuation rates are generally higher than seen with other reversible methods.
• The CuT380A is a good choice for nulliparous women and for many women with serious medical problems needing effective contraception .
• Same day placement is preferred. Immediate placement following abortion, C-section and vaginal deliveries have acceptable expulsion rates and give great convenience.
• The risks of IUD placement (infection, uterine perforation) are low, each about 1:1000.
• The most common side effects are increased bleeding and cramping; NSAIDs can provide effective treatment of these problems in most cases.
• The CuT380A is the most effective method of post coital contraception.
• The safety record with the CuT380A is impressive.
• The CuT380A offers convenient, private contraception, which reduces the risk of ectopic pregnancy and endometrial cancer.
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